Edition:
India

Leap Therapeutics Inc (LPTX.OQ)

LPTX.OQ on NASDAQ Stock Exchange Global Market

8.35USD
1:30am IST
Change (% chg)

$-0.02 (-0.24%)
Prev Close
$8.37
Open
$8.32
Day's High
$8.41
Day's Low
$8.20
Volume
6,864
Avg. Vol
18,853
52-wk High
$10.25
52-wk Low
$4.94

Latest Key Developments (Source: Significant Developments)

Leap Therapeutics Reports Qtrly Loss Per Share Of $0.85
Friday, 11 May 2018 

May 11 (Reuters) - Leap Therapeutics Inc ::LEAP THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.QTRLY LOSS PER SHARE $0.85.CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES TOTALED $35.4 MILLION AT MARCH 31, 2018.  Full Article

Leap Therapeutics Files For Resale Of Up To 3.73 Mln Shares Of Co's Common Stock By Selling Stockholders
Saturday, 9 Dec 2017 

Dec 8 (Reuters) - Leap Therapeutics Inc ::LEAP THERAPEUTICS INC FILES FOR RESALE OF UP TO 3.73 MILLION SHARES OF CO'S COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING.  Full Article

Eli Lilly And Co reports 17.5 pct passive stake in Leap Therapeutics ‍​as of Nov 14
Thursday, 23 Nov 2017 

Nov 22 (Reuters) - Eli Lilly And Co :Eli Lilly And Co reports 17.5 percent passive stake in Leap Therapeutics Inc‍​ ‍​as of November 14 - SEC Filing.  Full Article

Leap Therapeutics announces $18 million private placement offering
Wednesday, 15 Nov 2017 

Nov 15 (Reuters) - Leap Therapeutics Inc ::Announces $18 million private placement offering.Upon closing of transaction, leap will sell 2.96 million shares of unregistered common stock​.Signed voting agreement with HealthCare Ventures to vote shares in favor of approval proposed at stockholders​ special meeting.To sell shares in private placement with select institutional investors, strategic partners, including HealthCare Ventures, Eli Lilly.  Full Article

Leap Therapeutics qtrly loss per share $0.73
Monday, 13 Nov 2017 

Nov 13 (Reuters) - Leap Therapeutics Inc -:Leap Therapeutics reports third quarter 2017 financial results and announces first patient dosed with DKN-01 and Keytruda® (pembrolizumab) in esophagogastric cancer trial.Leap Therapeutics Inc - ‍cash, cash equivalents and marketable securities totaled $14.2 million at September 30, 2017​.Leap Therapeutics Inc - ‍net loss was $6.8 million for Q3 of 2017, compared to $7.3 million for same period in 2016​.Leap therapeutics inc - qtrly loss per share $0.73.  Full Article

BRIEF-Leap Therapeutics Files For Mixed Shelf Of Up To $100 Mln

* LEAP THERAPEUTICS INC FILES FOR MIXED SHELF OF UP TO $100 MILLION - SEC FILING ‍​ Source text : (http://bit.ly/2I0IyH4) Further company coverage: